CRISPR Therapeutics (CRSP) Reports $116M FY25 Revenue Driven by CASGEVY Growth

CRISPR Therapeutics reported a revenue of $116 million for FY25, attributing much of this growth to its product CASGEVY. The company's positive results reflect strong market demand for its gene editing technologies, potentially predicting further growth. CRSP's revenue guidance has raised optimism among investors and analysts alike. As the biotech sector continues to thrive, CRISPR's focus on innovative therapies positions it strongly in the market. This substantial growth could lead to increased investor confidence and higher stock valuations in the near term.